S K Vaswani1, R G Hamilton. 1. Johns Hopkins University School of Medicine, Division of Allergy and Clinical Immunology, Baltimore, Maryland, USA.
Abstract
BACKGROUND: Antibodies have been used therapeutically to treat a variety of clinical conditions. The introduction of monoclonal antibodies and more recently, engineered humanized antibodies has greatly refined and expanded the therapeutic potential of this modality of treatment. LEARNING OBJECTIVES: To reinforce the reader's knowledge of the therapeutic application of antibody in the treatment for different diseases. More specifically, to enhance reader's understanding of basic methods employed in the production and clinical use of humanized antibodies. DATA SOURCE: The MEDLINE database was used to review the humanized antibody related literature. CONCLUSION: Humanized antibodies provide a novel approach for the treatment of a broad range of diseases. Expanded use will depend on improvement in their efficacy (avidity and specificity), demonstration of their safety, and reduction of their immunogenicity.
BACKGROUND: Antibodies have been used therapeutically to treat a variety of clinical conditions. The introduction of monoclonal antibodies and more recently, engineered humanized antibodies has greatly refined and expanded the therapeutic potential of this modality of treatment. LEARNING OBJECTIVES: To reinforce the reader's knowledge of the therapeutic application of antibody in the treatment for different diseases. More specifically, to enhance reader's understanding of basic methods employed in the production and clinical use of humanized antibodies. DATA SOURCE: The MEDLINE database was used to review the humanized antibody related literature. CONCLUSION: Humanized antibodies provide a novel approach for the treatment of a broad range of diseases. Expanded use will depend on improvement in their efficacy (avidity and specificity), demonstration of their safety, and reduction of their immunogenicity.
Authors: T K Hart; M N Blackburn; M Brigham-Burke; K Dede; N Al-Mahdi; P Zia-Amirhosseini; R M Cook Journal: Clin Exp Immunol Date: 2002-10 Impact factor: 4.330
Authors: D L Meyer; J Schultz; Y Lin; A Henry; J Sanderson; J M Jackson; S Goshorn; A R Rees; S S Graves Journal: Protein Sci Date: 2001-03 Impact factor: 6.725